The French Competition Authority Follows up Allegations of Anti-competitive Practices by Sanofi-Aventis to Exclude Fair Generic Competition for Plavix(R) (clopidogrel)

UTRECHT, The Netherlands, May 19, 2010 - Teva Santé, one of France's leading generic medicines
companies, has welcomed news that the French Competition Authority has agreed
to its request to investigate alleged anti-competitive practices by
Sanofi-Aventis aimed at preventing generic competition to its Plavix(R)
(clopidogrel) treatment.

In November last year, Teva Santé filed a complaint with the
French Competition Authority against alleged practices by Sanofi-Aventis
which, according to Teva Santé, had the effect of excluding generic drugs
competing with Plavix(R) including Teva's own clopidogrel generic medicine.

In its decision published yesterday, the French Competition
Authority said that it intends to carry out an in-depth investigation on
alleged behaviour by Sanofi-Aventis to shut out generic competition.

According to the Authority, Sanofi-Aventis' communications
toward scientists and practitioners emphasise differences between Plavix(R)
and competing generics (including Clopidogrel Teva Pharma 75 mg) without
revealing that these differences have no impact on the therapeutic efficacy
of the product, and that the generic formulation has been fully tested and
approved for use by medical authorities across Europe.

Dr. Gerard van Odijk, CEO of Teva Europe, welcomed the
Authority's ruling: "We believe in a fair and open market that delivers
affordable healthcare for patients and the taxpayer across Europe. The
Authority's decision to investigate Sanofi-Aventis' behaviour underlines our
view that such practices are likely to prevent access to competition and
damage the long-term interests of patients."

Maurice Chagnaud, CEO of Teva Santé, said: "Innovator
companies need to understand that they cannot use misleading practices to
prevent competition from therapeutically equivalent and effective generic
products. Generic medicines help make healthcare affordable, and we consider
that practices aimed at stifling fair competition are unlawful."

Teva Pharmaceuticals Europe BV

Computerweg 10, 3542 DR Utrecht, Netherlands

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in
Israel, is among the top 15 pharmaceutical companies in the world and is the
leading generic pharmaceutical company. The company develops, manufactures
and markets generic and innovative pharmaceuticals and active pharmaceutical
ingredients. Over 80 percent of Teva's sales are in North America and Western
Europe.

Media contact: Paul Williams, Teva Europe, +44(0)7798-582889, paul.williams at tevauk.com